|
In this case study, Dr. Arpeet Shah shares his approach to clarifying PI-RADS 3 results with the IsoPSA Test
|
|
Solving a PI-RADS 3 Dilemma: Exploring Dr. Arpeet Shah’s Approach
|
|
When a patient presents with elevated PSA and a PI-RADS 3 lesion, how should a clinician proceed?
|
|
Dr. Arpeet Shah with the Associated Urological Specialists recently shared a case study on how he manages this dilemma. In this case study, he ordered an IsoPSA Test in order to better understand the patient’s risk, and the result helped him decide whether to move forward with biopsy or to continue monitoring.
|
|
Watch this short case to see how the IsoPSA Test supports more confident risk stratification and decision-making in complex cases.
|
|
|
|
|
|
Earn CME Credits and Learn About Ancillary Testing
|
|
Interested in earning CME credits while evaluating ancillary tests like the IsoPSA Test for your practice?
|
|
The first installment in a 3-part CME program on ancillary testing is available: Dr. Aaron Berger with Associated Urological Specialists presents on “Guiding Prostate Cancer Diagnosis with Biomarker Testing.”
|
|
In this talk, Dr. Berger explores how technological advancements in ancillary testing are enabling clinicians to evolve their approach to prostate cancer diagnosis and risk assessment.
|
|
Register for the CME program to learn more.
|
|
|
This material concerns the IsoPSA Test, a laboratory developed test (LDT) from Cleveland Diagnostics, Inc., which is performed by CLIA-certified laboratories qualified to conduct high-complexity clinical testing and is only intended for use consistent with applicable CLIA requirements. When offered as an LDT, the IsoPSA Test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).
|
|
|
|
